Pretty good couple of days for Disc, up about 15% on no news I...

Pretty good couple of days for Disc, up about 15% on no news I could see. The success Disc has in generating investor interest and adding value for shareholders is in stark contrast to Clinuvel. I do note Disc has significant board level experience with Pharma backgrounds and I guess if they run webinars on half yearly results they would include the CEO and be performed with some level of professionalism but that's just a guess.

Clinuvel is only commercialised in EPP for now, and the leading drug candidate for Disc is targeting EPP, so it's possible to compare two biotechs primarily interested in the same market for a direct apples/apples comparison - although Clinuvel is much closer to expanding to the huge Vitiligo market than Disc is to progressing with anything else. Pretty clear there is a big difference in corporate governance between the two and obvious who is better in this area. Disc is many years off actually competing or even generating any sort of revenue, but they are proving much more successful in attracting investor interest despite the prospect of the company just losing money for many years to come, and with no guarantee they will ever get an FDA approval which would obviously be catastrophic for Disc. Clinuvel, well they have a monopoly in EPP for years to come, and if successful with Vitiligo they could likely become the standard of care for a disease that has worldwide incidence approximately 1% of the human race.

Loss making Disc makes significant losses, which is ok for this stage, but they may never even get that approval and they certainly don't make great profits like money-printing CUV yet they are valued at over $2.8 Billion AUD while CUV languishes at about 0.7 Billion (with $175M cash). Risk/reward hmmm. Amazingly Disc should probably raise a bit of funding and offer cash/shares to take over CUV - CUV already monopolise the market DISC is seeking to enter with their lead drug candidate and CUV are already profitable - seems like good business sense and risk management rather than pouring money down the drain with no guarantee of success in 4-5 years time. It is really an absurd situation when the hopeful in Disc has a valuation 4 times higher than the commercialised, highly profitable FDA, EMA approved market monopoliser in CUV which also has a Phase 3 running (the phase III clinical trial underway for the blockbuster indication Vitiligo with their ALREADY FDA approved and safe drug) - Disc certainly doesn't have that but a takeover would give it to them along with Stroke, VP, XP etc. This seems to be a good reason to list on the NASDAQ where Disc is listed and in hindsight CUV should have done this several years ago in my opinion.

All IMO DYOR